Disrupting insulin-like growth factor signaling as a potential cancer therapy
作者： Deepali Sachdev , Douglas Yee
DOI: 10.1158/1535-7163.MCT-06-0080
关键词:
摘要: The type I insulin-like growth factor receptor (IGF-IR) plays multiple roles in several cancers and increased circulating levels of factor-I (IGF-I) are associated with risk breast, colon, prostate cancers. Because IGF-II insulin signal via the (IR) to stimulate cancer cells, inhibition IR might be necessary totally disrupt action IGFs their receptors. This review describes well-recognized IGF-IR driving malignant phenotype, examines evidence that perhaps should also targeted inhibit effects IGF ligands cancer, strategies signaling highlights some key issues need considered as clinical trials targeting proceed. [Mol Cancer Ther 2007;6(1):1–12]
aacrjournals.org
sci-hub.se 参考文章(100)
Xihong Zhang, Douglas Yee, Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility Cancer Research. ,vol. 62, pp. 4369- 4375 ,(2002)
F C Kull, S Jacobs, Y F Su, M E Svoboda, J J Van Wyk, P Cuatrecasas, Monoclonal antibodies to receptors for insulin and somatomedin-C. Journal of Biological Chemistry. ,vol. 258, pp. 6561- 6566 ,(1983) , 10.1016/S0021-9258(18)32449-9
Shoshana Yakar, Lothar Hennighausen, Derek LeRoith, Ling Zhao, Yiping Wu, Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research. ,vol. 62, pp. 1030- 1035 ,(2002)
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360
Julie S. Hartell, Jeffrey S Miller, Deepali Sachdev, Douglas Yee, Shu Lian Li, Yoko Fujita-Yamaguchi, A Chimeric Humanized Single-Chain Antibody against the Type I Insulin-like Growth Factor (IGF) Receptor Renders Breast Cancer Cells Refractory to the Mitogenic Effects of IGF-I Cancer Research. ,vol. 63, pp. 627- 635 ,(2003)
M Pollak, M-J Blouin, J-C Zhang, J J Kopchick, Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer. ,vol. 85, pp. 428- 430 ,(2001) , 10.1054/BJOC.2001.1895
Yongfen Min, Hiroyuki Yamamoto, Sorena Nadaf, Kohzoh Imai, David P Carbone, Choon-Taek Lee, Hideto Ito, Yasushi Adachi, Fumio Itoh, Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Research. ,vol. 63, pp. 6432- 6441 ,(2003)
Douglas Burtrum, Zhenping Zhu, Dan Lu, Donna Marie Anderson, Marie Prewett, Daniel S Pereira, Rajiv Bassi, Rashed Abdullah, Andrea T Hooper, Henry Koo, Xenia Jimenez, Danielle Johnson, Robin Apblett, Paul Kussie, Peter Bohlen, Larry Witte, Daniel J Hicklin, Dale L Ludwig, None, A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo Cancer Research. ,vol. 63, pp. 8912- 8921 ,(2003)
F. Frasca, G. Pandini, P. Scalia, L. Sciacca, R. Mineo, A. Costantino, I. D. Goldfine, A. Belfiore, R. Vigneri, Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Molecular and Cellular Biology. ,vol. 19, pp. 3278- 3288 ,(1999) , 10.1128/MCB.19.5.3278
R M Hudziak, G D Lewis, M Winget, B M Fendly, H M Shepard, A Ullrich, p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Molecular and Cellular Biology. ,vol. 9, pp. 1165- 1172 ,(1989) , 10.1128/MCB.9.3.1165